Passage Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Passage Bio, Inc. - overview
Established
2018
Location
Philadelphia, PA, US
Primary Industry
Biotechnology
About
Established in 2018 and based in Pennsylvania, US, Passage Bio, Inc. operates as a biotechnology company that develops adeno-associated virus (AAV)-delivered therapeutics for the treatment of central nervous system diseases.
Current Investors
Frazier Healthcare Partners, OrbiMed Advisors, Versant Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Epidemiology, Pharmaceutical Research & Development
Website
www.passagebio.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.